The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCizzle Biotech Share News (CIZ)

Share Price Information for Cizzle Biotech (CIZ)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.70
Bid: 1.60
Ask: 1.80
Change: 0.00 (0.00%)
Spread: 0.20 (12.50%)
Open: 1.70
High: 1.70
Low: 1.70
Prev. Close: 1.70
CIZ Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Cizzle subscription raises GBP350,000 to fund development pipeline

Mon, 12th Jun 2023 10:15

(Alliance News) - Cizzle Biotechnology Holdings PLC said on Monday that it raised GBP350,000 from a subscription of 16.7 million shares at 2.1 pence per share, with new and existing investors.

The London-based diagnostics developer said that the funds raised will be used to continue the development of a laboratory-development test for early detection of lung cancer, progress the company's proprietary CIZ1B biomarker blood test, and commence development of its point of care rapid test for use in doctors' offices and pharmacies.

The CIZ1B biomarker blood test refers to research proving that a stable blood plasma biomarker, a variant of CIZ1, can be measured with a high sensitivity through an ELISA process, allowing for testing in a high-throughput, hospital-friendly format. This test is required for the early detection of lung cancer.

Cizzle announced that its loan facility agreement with E3 Fund SP, entered into on September 20 and amended on April 21, has been altered to allow the subscription to proceed at a premium to the fixed repayment price of the facility of 1.8p per share.

The company said the facility has been extended until December 8, and will be drawable in tranches of not less than GBP100,000 as request by the company or the investor.

Cizzle said the first drawdown will be available to the company following shareholder approval at the next general meeting, to allot 23.8 million new shares.

Repayment of the facility is to be by way of issues and allotment of new shares in the capital of the company, at a fixed price equal to the issue price of 2.1p per share.

Executive Chair Allan Syms said: "The funds raised from the subscription and converting the facility in full will provide continued momentum in bringing our proprietary novel technologies for detecting lung and other cancers at an early stage to thereby potentially preventing suffering and saving many lives."

Shares in Cizzle Biotechnology were down 8.8% at 2.17 pence in London on Monday.

By Will Neill, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
23 Dec 2022 18:15

TRADING UPDATES: Fiinu teams with TransUnion; GRC wins pact

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
23 Nov 2022 16:58

IN BRIEF: Cizzle Biotechnology signs lung-cancer study in China

Cizzle Biotechnology Holdings PLC - London-based diagnostics developer - Signs further Memorandum of Understanding with International Co-Innovation Centre for Advanced Medical Technology for a clinical pilot study with the Cancer Hospital Chinese Academy of Medical Sciences, National Cancer Center of China. The clinical pilot study will evaluate optimised assays using a monoclonal antibody that Cizzle Biotechnology has developed that specifically detects CIZ1B, which is highly associated with stage 1 lung cancer.

Read more
9 Nov 2022 20:41

UPDATE: Cizzle, Vela Technologies notes planned Conduit Pharma merger

Cizzle Biotechnology Holdings PLC - London-based diagnostics developer - and Vela Technologies PLC - Bradford, England-based investment firm focused on early-stage and pre-IPO disruptive technology investments - Notes announcement by Conduit Pharmaceuticals Ltd that it intends to become a publicly traded company on the Nasdaq in the US through a merger with special purpose acquisition firm Murphy Cannon Acquisition Corp. The deal is expected to generate USD149.7 million worth of proceeds for Conduit.

Read more
28 Sep 2022 14:43

Cizzle Biotechnology reports narrowed loss as passes "key milestones"

(Alliance News) - Cizzle Biotechnology Holdings PLC on Wednesday said it had passed "key milestones" as it moved towards generating revenue for its products.

Read more
18 Aug 2022 11:37

Vela Tech, Cizzle Biotech shares jump on investee's trial results

(Alliance News) - Vela Technologies PLC and Cizzle Biotechnology Holdings PLC on Thursday hailed the latest clinical trial results from investee St George Street Capital Ltd.

Read more
5 Jul 2022 12:15

Cizzle Biotechnology expands use of lung cancer test

(Alliance News) - Cizzle Biotechnology Holdings PLC on Tuesday said that it is using its early-stage lung cancer test technology to detect more cancer types, notably breast cancer.

Read more
20 Jun 2022 15:40

UK shareholder meetings calendar - next 7 days

Tuesday 21 June 
1Spatial PLCAGM
Altus Strategies PLCAGM
Coca-Cola HBC AGAGM
FireAngel Safety Technology Group PLCAGM
HC Slingsby PLCAGM
HSS Hire Group PLCAGM
Mission Group PLCAGM
Novacyt SAAGM
Pendragon PLCAGM
RTW Venture Fund LtdAGM
Velocys PLCAGM
Wednesday 22 June 
ASA International Group PLCAGM
Atalaya Mining PLCAGM
Bonhill Group PLCAGM
Chapel Down Group PLCAGM
Churchill China PLCAGM
Downing Renewables & Infrastructure Trust PLCGM re share issue
Ecofin US Renewables Infrastructure Trust PLCAGM
EJF Investments LtdAGM
Frenkel Topping Group PLCAGM
Good Energy Group PLCAGM
Honeycomb Investment Trust PLCAGM
ICG-Longbow Senior Secured UK Property Debt Investments LtdAGM
Intelligent Ultrasound Group PLCAGM
Iofina PLCAGM
John Wood Group PLCAGM
Kingfisher PLCAGM
LXi REIT PLCGM
Menhaden PLCAGM
North Atlantic Smaller Cos Investment Trust PLCAGM
Pennant International Group PLCAGM
Plant Health Care PLCAGM
Skillcast Group PLCAGM
Team PLCAGM
Tribal Group PLCGM re final dividend
Trident Royalties PLCAGM
Vertu Motors PLCAGM
Wentworth Resources PLCAGM
Thursday 23 June 
Avacta Group PLCAGM
Anglo Asian Mining PLCAGM
Card Factory PLCAGM
Cordiant Digital Infrastructure LtdAGM
Downing Renewables & Infrastructure Trust PLCGM re initial placing & open offer
Eight Capital Partners PLCGM re aligning 2022 bonds with 2026 bonds
GENinCode PLCAGM
Ideagen PLCGM re takeover by Hg Pooled Management Ltd
Longboat Energy PLCAGM
Oxford Nanopore Technologies PLCAGM
Puma VCT 13 PLCGM re cancellation of listing & liquidation
RBG Holdings PLCAGM
Tandem Group PLCAGM
Union Jack Oil PLCAGM
Zinnwald Lithium PLCAGM
Friday 24 June 
AFC Energy PLCGM re fees for non-executive directors
Avast PLCAGM
Devolver Digital IncAGM
Entain PLCAGM
Gulf Keystone Petroleum LtdAGM
Hawkwing PLCAGM
Invesco Bond Income Plus LtdAGM
Life Science REITAGM
Northcoders Group PLCAGM
Princess Private Equity Holding LtdAGM
Monday 27 June 
Anglo-Eastern Plantations PLCAGM
Celadon Pharmaceuticals PLCAGM
Cizzle Biotechnology Holdings PLCAGM
Echo Energy PLCAGM
Medica Group PLCAGM
Pelatro PLCAGM
Surgical Innovations Group PLCAGM
Warpaint London PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
16 Jun 2022 16:55

TRADING UPDATES: Valereum opens NFT market; Conygar considers raising

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
30 May 2022 12:32

IN BRIEF: Cizzle Biotechnology widens annual loss on acquisition costs

Cizzle Biotechnology Holdings PLC - London-based diagnostics developer - Posts higher annual loss in 2021. Pretax loss widens to GBP4.0 million from GBP14,000 in 2020. In May 2021, Cizzle was bought by Bould Opportunities PLC. Acquisition-related costs stand at GBP3.1 million in 2021 versus none in 2020.

Read more
6 May 2022 11:18

AIM WINNERS & LOSERS: SDI upbeat; Westminster rises on contract win

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
6 May 2022 10:11

Cizzle Biotechnology shares jump on US lung cancer collaboration

(Alliance News) - Cizzle Biotechnology Holdings PLC on Friday announced a new collaboration into lung cancer testing with a US partner.

Read more
11 Apr 2022 21:14

TRADING UPDATES: WANdisco bookings up; STM legal appeal denied

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
8 Mar 2022 06:45

IN BRIEF: Cizzle Biotech notes promising data from Arcadia study

Cizzle Biotechnology Holdings PLC - London-based diagnostics developer - Reports that Arcadia clinical study shows potential value of AZD1656 treatment for Covid-19 patients. The new data analysis comes from St George Street Capital Ltd, which runs the trial with Excalibur Medicines Ltd for the treatment, in which Cizzle holds a "significant" royalty-bearing economic interest.

Read more
14 Feb 2022 15:26

Cizzle Biotechnology acquires further 5% interest in Covid treatment

(Alliance News) - Cizzle Biotechnology Holdings PLC shares jumped on Monday after it announced that it acquired an additional 5% interest in the commercialisation of the Covid-19 treatment AZD 1656.

Read more
3 Feb 2022 22:31

TRADING UPDATES: Alliance Pharma to appeal; Braemar sales to rise

TRADING UPDATES: Alliance Pharma to appeal; Braemar sales to rise

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.